TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Opioid abstinence at the end of phase 1
Endpoint domain: Mortality/survival
Primary endpoint: Opioid abstinence at the end of phase 2
Endpoint domain: Mortality/survival
Primary endpoint: Treatment responders at the end of treatment
Endpoint domain: Mortality/survival
Primary endpoint: MenC bactericidal titers above the protective threshold (rSBA ≥ 1:8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antipolyribosylribitol phosphate Ig ≥ 1.0 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persistence of MenC antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: long term renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CGI-P scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BSFQ scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Aggression as measured by the MOAS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year disease-free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Intrauterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid retrieval time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity in predicting microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Specificity in predicting microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area-under-the-curve for UAC and ACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Death within 7 days of life and/or moderate or severe hypoxic-ischemic encephalopathy
Endpoint domain: Mortality/survival
Primary endpoint: psychosocial functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient reported outcomes (PROs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean AUC_hyd/AUC_bup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score on day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in protein C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 5-year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: recurrence-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CCL4 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: systemic postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity and Mortality of Patients With Chronic Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Self-Rated Health (SRH)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Rated Wellbeing (SRW)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of men with positive depression screen (PHQ-2 scores ≥3)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle strength of the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of motivational interviewing intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean arterial blood pressure drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: motor blockade scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proteinuria screening completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decline in hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fluid balance >1,500 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum osmolality >300 mosmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cl >108 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child mortality
Endpoint domain: Mortality/survival
Primary endpoint: Quality of DanShen RCTs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bond strength to root dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores on the visual-analog pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of lower-lip anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Programming time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Seroconversion rates for type 1 and type 3 poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of withdrawal movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonia event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke index reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Longitudinal LV systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: bleeding mortality
Endpoint domain: Mortality/survival
Primary endpoint: Distance travelled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accelerometer vector magnitude activity counts (VM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: long-term symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ileal distension performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel wall visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in inspiratory muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pimax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tlim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participation in strength exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nutritional behaviours (fat avoidance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acetylcholine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients receiving a prescription at discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time of immobilisation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean percentage change in lipid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MEMS based adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression (Montgomery-Asberg Depression Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of cortisol production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of visual attention efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bolus insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen cost per meter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate response per meter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed during stair ascending and descending
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurring heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work-related problems with alcohol
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient's satisfaction with disease status (PatSAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SF‐SACRAH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snoring level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inhibition of TF expression in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of gastric injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diuretic efficiency (DE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60 day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in CGI-S
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: skin conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: interfacial toughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Train-of-four ratio at extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reintubation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of IASCC
Endpoint domain: Mortality/survival
Primary endpoint: Muscle cramp frequency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle cramp severity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Binding potential ratios of olanzapine and quetiapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: H1RO values in the cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: YBOCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates (decrease in YBOCS scores ≥ 25%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of excellent response (YBOCS score ≤ 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of recurrent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative MACE-free survival
Endpoint domain: Mortality/survival
Primary endpoint: mean medial and lateral tibial slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean coronal tibial slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: within-subject difference between medial and lateral tibial slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion potentiated effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intensive care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of stoma creation
Endpoint domain: Adverse events/effects
Primary endpoint: biomarkers of tissue destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of cartilage degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of synovial inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in rest arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase of maximum load (max MET'S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PlGF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sEng concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active mobility in forward elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative blood hemoglobin increase (delta Hb[g/dl])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homologous blood transfusion (HBT) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful bag‐mask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean number of days immobilized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma triglyceride decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high density lipoprotein cholesterol increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subthreshold depression prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-test probability of viable pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post-test probability of complete miscarriages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Predictive accuracy of clinical judgement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: antepartum visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: postpartum hospital duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration in labor and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in HamD17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue scale for individual problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Health Questionnaire-PF50 6-month-change score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: survival free of disabling stroke and reoperation
Endpoint domain: Mortality/survival
Primary endpoint: insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: tobacco abstinence at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in liver fibrosis stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive glucose pattern during the 4 h-OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: some dexterity in the paretic arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete functional recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin dermatitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: first-fit success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in axial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reappearance or worsening of dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Time from collecting to reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regression of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS after the bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for supplemental bolus injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: N2O concentration in breathing zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sickness leave
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient knowledge about diabetes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: reduction of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in physical limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improvement in general state of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psoriasis Area and Severity Index 75 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Localization of P50 and N100 ECD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of syncope or presyncope
Endpoint domain: Adverse events/effects
Primary endpoint: No fluid on optical coherence tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: C-telopeptide of type II collagen (CTX-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of erectile dysfunction (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of PIVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of PIVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peri-implant bone loss (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthesis success rates
Endpoint domain: Mortality/survival
Primary endpoint: mothers' %VPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: role modeling
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Severe bleeding occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Severe nasal pain occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term monitoring and support for physical activity and exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-min walking distance (12MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nail-fold microcirculation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma endothelin-1 level elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum IgG level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Family breakfast frequency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in HbA1c from baseline at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hemoglobin decline at week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Interventional examination time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes